MOLMED S.p.A. is a medical biotechnology company focused on oncology and genetic orphan diseases, listed on the Milan Stock Exchange (MLM). The company was founded in 1996 between Boehringer Mannheim and Science Park Raf, from 2000 onwards MOLMED has evolved into a biopharmaceutical company which covers all functions, from discovery to proof of clinical activity. MOLMED is located in Milan, Italy, in the San Raffaele Biomedical Science Park. This location offers crucial advantages, allowing MOLMED to complement its own R&D resources with the cutting-edge scientific, technological and clinical resources of its host institution.

The role of MOLMED is to develop protocols transferable-to-the-clinic and scientifically sound assays for the technology developed for the two proposed gene therapy applications and to contribute significantly in the exploitation of the relevant results obtained within the project.